The short answer
Available evidence does not establish that SAMe combined with clozapine causes serotonin syndrome. General warnings about SAMe and serotonin-raising medicines should not automatically be applied to every psychiatric medicine. Discuss SAMe with the treating team because the full medication list and psychiatric history matter.
What this answer covers
Oral S-adenosylmethionine supplements; not methionine, endogenous SAM metabolism or injected formulations.
- Supplement or preparation
- S-Adenosylmethionine
- Medication ingredient
- clozapine
What the warning means
NCCIH describes possible SAMe interactions with medicines and supplements that raise serotonin. Clozapine is an antipsychotic whose proposed therapeutic actions include blocking serotonin 5-HT2A and dopamine D2 receptors. Those facts alone do not establish a SAMe-clozapine serotonin-syndrome interaction, and receptor pharmacology cannot guarantee safety.
What an antidepressant trial found
A six-week study of 73 people added SAMe or placebo to a serotonin reuptake inhibitor. Adverse-event discontinuation did not differ significantly between groups. This limited tolerability result does not exclude rare serotonin toxicity and does not tell us the risk with clozapine.
Psychiatric history matters
NCCIH cautions that SAMe may worsen mania in people with bipolar disorder and advises supervision when it is used for depressive symptoms. That concern is separate from a proven clozapine interaction. Tell the treating team why you want SAMe and about previous periods of unusually elevated mood or reduced need for sleep.
Review all medicines together
The relevant question includes any antidepressants and other supplements taken alongside clozapine. Bring the exact SAMe product and full medication list for review before starting it. Neither the antidepressant trial nor the clozapine label establishes a protective spacing interval or a clozapine dose adjustment for SAMe.
Evidence and practical considerations
Side effects & toxicity
General serotonergic medicine guidance and an SRI augmentation trial are not direct evidence for clozapine-associated serotonin syndrome.
- Exact scope
- Oral S-adenosylmethionine supplements; not methionine, endogenous SAM metabolism or injected formulations. with Oral clozapine, RxNorm 2626 IN.
- Medication form and route
- oral clozapine; oral supplement
What remains uncertain
- No quantified clozapine-specific interaction or validated spacing intervention.
Factors that may matter: Exact preparation; Other medicines and baseline clinical status.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed clozapine.
Clozapine causes sedation and impaired performance, can contribute to falls, and carries dose-related seizure risk. CYP1A2, CYP3A4 and CYP2D6 participate in metabolism. Proposed therapeutic activity includes dopamine D2 and serotonin 5-HT2A receptor antagonism.
How this applies: Medication-specific safety context only; no direct botanical interaction or automatic dose change is established.
No named interaction with these counterparties or measured combined risk.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the named supplement.
Possible interactions with agents that increase serotonin; people with bipolar disorder should use SAMe for depression only with clinician supervision because mania may worsen.
How this applies: Supplement-specific guidance interpreted alongside the clozapine label.
General guidance does not quantify a clozapine interaction or establish protective spacing.
Source 3: original human clinical study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 73 serotonin-reuptake-inhibitor nonresponders with major depression.
Response and remission improved; adverse-event discontinuation did not differ significantly (5.1% versus 8.8%).
How this applies: Interpret only within the stated preparation, population and endpoints.
Not clozapine or its usual population. Abstract does not provide formal serotonin-syndrome ascertainment and cannot establish rare-event safety.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared evidence-based article with explicit preparation and endpoint limits. | |
| Research summary published |
Article revision: 824e4d7f451e2e33
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.